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Abstract
Statins are very effective for lowering low-density lipoprotein cholesterol for primary 
and secondary cardiovascular disease prevention. While statins are usually well toler-
ated, individual response to statin therapy varies and intolerance, predominantly muscle 
symptoms, may appear in a significant proportion of patients. Besides clinical factors, 
variation in genes coding for proteins with drug transporting, immune or enzymatic 
function have been implicated in the pathogenesis of statin intolerance. In this review, 
we will characterise the candidate gene variants for development of statin intolerance, 
describe their population distribution and summarise current knowledge on their bio-
logical plausibility. Clinical relevance and current guidelines/recommendations will be 
also discussed.
Keywords: genetic variation, pharmacogenetics, SLCO1B1, statin, statin-induced 
myopathy
1. Introduction
Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase) inhibitors are highly effective 
drugs lowering plasmatic concentration of LDL-C cholesterol by 30–50% [1]. Despite the fact 
that they are usually considered safe and very well tolerated, a significant proportion of the 
treated patients does not tolerate the drug: they suffer from side effects, which may result in 
non-compliance of patients, drug dose-lowering and even discontinuation of therapy [2–4]. 
Undesirable effects of statins restrict their administration or reaching LDL-C cholesterol tar-
get values and limits effective treatment of patients at risk. Non-adherence or discontinuation 
of therapy is associated with an increased risk of cardiovascular events [5–7].
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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By analogy to individual nature of patients´ response to treatment [8–10] there are also inter-
individual differences in occurrence and extent of statin intolerance and its symptoms. The 
knowledge of the risk factors predisposing for intolerance development including character-
istic genetic background is crucial for its understanding and prevention. In this chapter we 
will review the polymorphic gene variants implicated in development of statin intolerance, 
briefly describe their biological plausibility and characterise clinical relevance.
2. Statin intolerance
Statin intolerance is the inability to tolerate sufficient dose of statin needed to reduce cardio-
vascular risk due to side effects or intolerance to treatment [11]. The most frequent are muscle 
symptoms characterised bellow.
2.1. Statin-associated muscle symptoms
Statin-induced muscle symptoms range from myalgia to mild or severe myopathy and even 
to rare rhabdomyolysis [12]. The symptoms appear in about 75% in the first 10–12 weeks and 
in 90% of cases in the first 6 months after treatment initiation or dose up titration [13]. The true 
frequency muscle related side effects has been widely debated: while an observational study 
reported as much as about 20% of patients on statins [14], clinical trial data suggests frequen-
cies to be equal or lower than 5% [15], however there was a study reporting that clinical trials 
did not use a standard definition for statin myalgia [16], which may result in underestimated 
occurrence of statin-induced muscle symptoms. In any case, given very high usage of statins 
(the third most frequently prescribed drug), even lower relative frequency numbers would 
mean substantial absolute number of symptomatic patients.
2.2. Clinical-related risk factors
The available data shows that the side effects of statin therapy are group-dependent, time-
dependent and dose-dependent; their frequency is greater at a higher statin dose [17].
Endogenous factors known to increase occurrence of side effects are as follows: another 
lipid-lowering therapy, alcohol abuse, surgery, heavy exercise. Importantly, interactions with 
medication may be serious [18]; particularly drug interactions likely contribute the suscepti-
bility to statin related muscle symptoms [19].
Further factors predisposing to statin intolerance are: advanced age (>70 year), female sex, 
race/ethnicity, family history of muscle disorders, vitamin D deficiency, history of creatine 
elevation, hepatic and renal impartment, hypothyroidism, low body mass index [20].
2.3. Genetic factors
Besides the above characterised factors, genetic “make-up” of a given patient is important 
component in susceptibility to statin intolerance. Indeed, genetic variation represents the 
major factor responsible for inter-individual differences in patient responsiveness and their 
inclination towards undesirable side effects of statins.
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3. Genes responsible for statin intolerance
The following section characterises the gene variants that have been implicated in mecha-
nisms of statin intolerance represented by statin-induced myopathy. These are listed in the 
Table 1.
3.1. SLCO1B1 gene
SLCO1B1 gene encodes the OATP1B1 (organic anion transporting polypeptide), which has been 
reported to regulate the hepatic uptakes of statins [27, 28]. Strong support for its nomination as a 
risk factor for statin intolerance came from the GWAS study which investigated genetic variation 
in 85 subject with myopathy and 90 controls, all taking 80 mg of simvastatin [21]: strong asso-
ciation was identified between statin-induced myopathy and single nucleotide polymorphism 
(SNP) rs4363657 located within the SLCO1B1 gene. This noncoding SNP was in nearly complete 
linkage disequilibrium with the nonsynonymous rs4149056 SNP variant, which has been linked 
to statin metabolism: the odds ratio for myopathy was 4.5% per one copy of the C allele and 
16.9% in CC homozygotes compared with homozygotes for standard allele (TT). More than 60% 
of observed myopathy cases could be attributed to this particular genetic variation, [21], which 
is also due to its relatively high population prevalence - rs4149056 C allele frequency is 15%.
3.2. LILRB5 gene
A potential role for immune system genetic variation in development of statin-induced myop-
athy has been recently reported for a variant in leukocyte immunoglobulin-like receptor sub-
family-B, LILRB5 gene (rs12975366:T > C:Asp247Gly) [25]. The missense variant Asp247Gly 
has been associated with serum creatine kinase (CK) levels; the mean levels of this enzyme 
were elevated in Asp247 homozygotes (TT). The LILRB5 Asp247 homozygous genotype has, 
therefore, been associated with increased risk of statin intolerance [25]. No independent rep-
lication data on this plausible new variant has been available so far.
Gene Chromosome Allele rs number Coding variation Study
SLCO1B1 12p12.2 *5 ≠ rs4149056 521 T > C [21]
CYP2D6 22q13.1 *3 rs35742686 2549delA [22]
*4 rs3892097 splicing defect, G > A
*5 gene deletion
CYP3A4 7q21.1 *1B rs2740574 -392A > G transition [23]
GATM 15q15.3 — rs9806699 G > A, cis-e QTL [24]
LILRB5 19q13.4 — rs12975366 T > C: Asp247Gly [25]
COQ2 4q21.22-q21.23 — rs6335454 synonymous [26]
— rs4693075 non-coding
Note: rs, reference sequence; ≠ denotes haplotype (not allele) designation, see Section 4, second paragraph.
Table 1. Gene and their variants implicated in development of statin intolerance presented as statin myopathy.
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3.3. GATM gene
Glycine amidinotransferase, GATM gene encodes a mitochondrial enzyme, which is involved 
in creatine biosynthesis. SNP rs9806699 within the GATM gene has been associated with statin 
induced myopathy, specifically minor allele A conferring a protective effect and reduced risk 
of myopathy [24]. However, as this result was not replicated [29], further investigations are 
required before a possible role for this variation in statin tolerance is clarified.
3.4. Family of cytochrome P450 genes
The cytochrome P450 family is a group of izoenzymes important for catalysing oxidation of 
xenobiotics. There is a wide spectrum of polymorphic variants affecting various pharmaco-
genetics aspects. Regarding cardiovascular setting, CYP gene variation plays role in warfa-
rin and clopidogrel metabolism with clear clinical relevance (e.g. [30]). In context of statin 
adverse drug reaction, Mulder et al. [22] reported higher incidence of statin intolerance in 
the group of patients who carried two of the less effective CYP2D6 *3,*4,*5 alleles. Regarding 
another gene within cytochrome P450 system, namely CYP3A5, an association was observed 
between nonfunctional CYP3A5*3 allele and the magnitude of CK elevation in case of patients 
experiencing myalgia during atorvastatin treatment [23]. Importantly, patients who develop 
myalgia while taking atorvastatin were more likely to experience a greater degree of muscle 
damage if they express two copies of CYP3A5*3.
3.5. Other plausible gene variants
COQ2 gene encodes Coenzyme Q2, involved in synthesis of ubiquinon (Coenzyme Q10, 
CoQ10), a redox carrier in the mitochondrial respiratory chain and a lipid-soluble antioxidant. 
Two variants within the COQ2 gene (Table 1) have been associated with increased odds of 
statin intolerance, defined primarily through muscle symptomatology [26]. This observation 
has been subsequently replicated [31].
From other molecules functioning as drug transporters, ABCB1 gene variation may also par-
ticipate in development of statin muscle symptoms. This gene encodes the P-glycoprotein, an 
independent efflux pump. From its variants, the 1236 T, 2677non-G, and 3435 T alleles were 
less frequent in cases undergoing statin therapy than in the control group [32]. The authors 
also demonstrated a reduced T-non-G-T haplotype frequency (20.0%) in patients in whom 
myalgia developed during simvastatin treatment, as compared with the control, non-myalgia 
group (41.4%).
Most recently, a variant of a UGT1 gene coding for uridine diphosphate glucuronosyltrans-
ferase, specifically UGT1A1*28 variant allele (rs8175347), was reported to possess plausible 
protective effect in development of statin intolerance [33], however again this finding must 
be replicated.
In the following text we will concentrate on the SLCO1B1 gene variation and describe its 
population distribution and clinical relevance. The reason for our focus is that to date, the 
rs4149056 SLCO1B1 variant has been repeatedly evidenced to possess the strongest effect in 
response to statin therapy.
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4. Genetic variability and population distribution of SLCO1B1
More than 45 nonsynonymous variants in SLCO1B1 gene have been identified [34]. Some of 
the variants have altered function [35]. Genotypic frequencies of SLCO1B1 variants depend 
on ethnicity, and genetic difference between populations correlated with the geographical 
distances [34, 36, 37]. In particular, single nucleotide polymorphism the 521 T > C (rs4149056) 
appeared more commonly in European-Americans while it was less frequent in African-
Americans. In opposite, single nucleotide polymorphism the 388A > G (rs2306283) was 
detected predominantly in African-Americans. Pasanen et al. [38] investigated the frequen-
cies of 12 SNPs in SLCO1B1 in 941 persons from 52 populations across Europe, Asia, Africa, 
Middle East, Oceania and the Americas (Amerindians).
SLCO1B1 single nucleotide polymorphisms 521 T > C and 388A > G form four haplotypes: 
*1A (388A/521 T), *1B (388G/521 T), *5 (388A/521 T) and *15 (388G/521C) [38, 39]. The low 
activity haplotypes–*5 (388A/521C) and *15 (388G/521C) occur with combined haplotype 
frequency of approximately 15–20% in Europeans, 10–15% in Asians, 2% in sub-Saharian 
Africans. The *1B (388G/521 T) haplotype occurs in approximately 26% Europeans, in 39–63% 
Asians and in 77% sub-Saharian Africans. The haplotypes *5 and *15 are associated with sig-
nificant reductions of statin hepatic uptake [40], resulting in increase of systemic substrates 
exposure.
5. Clinical relevance of the variation in the SCLO1B1 gene
Clinical relevance of the SCLO1B variation is based on biological role of its gene products in 
hepatic transport of statins. Statins are mainly delivered within hepatocytes to their site of 
actions by uptake transporters and eliminated into the bile by eflux transporters [41]. Many 
statins are substrates of hepatic uptake transporters including OATP1B1, OATP2B1 and 
OATP1B3 [28] with OATB1B1 as the main one. The loss of function the SLCO1B1*5 (Val174Ala, 
521 T > C, rs4149056), located in exon 5, downregulates OATB1A1 transporter cell membrane 
and protein expression [42] which leads to decreased hepatic uptake, greater systemic statin 
plasma concentrations, and therefore greater muscle statin exposure, all these resulting in 
adverse effects [20, 36, 43–45].
Importantly, the impact of the rs4149056 variant on statin metabolism appears to differ 
between distinct statins. The effect of rs4149056 genotypes was much greater for simvas-
tatin, less for atorvastatin and rosuvastatin in healthy volunteers [46, 47]: For simvastatin 
the area under curve, AUC (0-infinity) was increased by 221% in genotype CC individuals 
in compared with wild-type TT individuals. For atorvastatin this parameter was increased 
by 145% and for rosuvastatin by 62%. Individuals carrying C allele also reached maximum 
concentration (Cmax) earlier, and its value was 200% higher compared with TT individu-
als of rs4149056 [47]. Further, the rs4149056 polymorphism was significantly associated with 
simvastatin treatment cases of severe statin induced myopathy, which did not occur after 
atorvastatin [45] or pravastatin [48] treatment. Similar conclusions regarding simvastatin 
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were obtained in animal model, again for simvastatin however not for pravastatin or atorvas-
tatin [49]. Table 2 lists main studies investigating effect of simvastatin on statin intolerance/
myopathy in humans.
It is crucial that in agreement with the rules for performing association studies [50] the data 
obtained in the SEARCH study has been independently replicated within the Heart Protection 
Study, in 10,000 patients who received 40 mg Simvastatin [21]. The meaningful data obtained 
in this way provided starting point for reflection of the observations from genetic and phar-
macokinetic studies into clinical practice, including formulation of treatment recommenda-
tions which will be subject of the next section of our chapter.
6. Testing for statin intolerance in clinic–current status and treatment 
recommendations
The spectrum of evidence supporting the association between the lead SNP rs4149056 and 
statin, namely simvastatin-induced myopathy prompted application of the SLCO1B1 geno-
typing for clinical usage. This translation to diagnostics aims mainly at reducing risk of sim-
vastatin induced muscle toxicity and at increased adherence to therapy [43, 51, 52]. Another 
possible outcome of genotyping is the option to use alternate agents of the statin class.
In clinical practice, the adverse effect of SLCO1B1 polymorphism depends on the genotype (being 
highest in homozygotes), statin dose and statin type. This has been reflected in the guidance for 
prescribers provided primarily by the Clinical Pharmacogenetics Implementation Consortium 
(CPIC); the working group produces guidelines for simvastatin use in individual carriers risk allele 
in SLCO1B1 gene [43]; the guidelines have been recently updated [53]. In patients with one or two 
copies of SLCO1B1 rs4149056 C allele, simvastatin should be avoided or reduced dosage should 
be considered, pravastatin or rosuvastatin are preferred alternatives according to the CPIC guide-
lines, however other clinical and patients specific factors should be taken into account [43, 53].
Apart from this general, non-compulsory guidance, there have been more systematic efforts to 
apply SLCO1B1 genotyping into practice. This direction is represented e.g. by pre-emptive pro-
grams performed from the initiative by U.S. Pharmacogenetics Research Network at eight sites 
[54]. Similarly, aiming of introducing genotype-guided prescribing, pre-emptive genotyping has 
Study Simvastatin dose Outcome Reference
SEARCH 80 mg OR 4.5 per C allele [21]
OR 16.9 for CC homozygotes
Heart protection study 40 mg OR 2.6 per C allele [21]
Brunham 10-80 mg OR 2.3 per C allele [45]
Note: OR, odds ratio.
Table 2. Basic studies that have reported a strong association between the rs4149056 single nucleotide polymorphism 
and simvastatin induced myopathy.
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also been investigated in Europe by the EU Horizon 2020-funded Ubiquitous Pharmacogenomics 
(U-PGx) Consortium (http://upgx.eu) in seven European countries [55]. Last but not least, recom-
mendations were formulated also on a national level - in France: the French National Network of 
Pharmacogenetics (RNPGx) [56] is in favour of rs4149056 testing before starting therapy or early 
after treatment onset in patients with one or more risk factors. If the genotype is not known early, 
the RNPGx considers that a polymorphism test is potentially useful also in the event of already 
occurring muscle toxicity in patients treated with statins, in order to rule out or confirm a genetic 
cause. From the above examples it is clear that pharmacogenetic genotyping for prediction/con-
firmation of statin intolerance undergoes ongoing development and progress; further updates 
of the recommendations are expected. It should be noted that there have been opinions as well 
that the current status of knowledge has not been yet sufficient to allow clinical application of 
genotyping for risk of statin intolerance [52]. There have been several arguments, however espe-
cially those economical (“the tests are too costly”) are not substantiated; some “con” opinions 
have been also “traditionalistic”, from conservative point of view on doubting any new test or 
medical management measure including pharmacogenetics. However, this reluctant or at least 
“sceptical” attitude about pharmacogenetic contribution to routine statin usage, well known also 
from other applications of pharmacogenetics, has been gradually changing–it only takes time, 
systematic information on the evidence and particularly education to overcome it [57].
7. Future perspectives including economic aspects of genetic test for 
statin intolerance
Implementation of a genetic test for statin intolerance into routine practice definitely requires 
analysing its benefits not only for patients but also for health care providers. In this context, phar-
macoecomic data on genetic testing statin intolerance have been scarce. The existing literature 
on cost-effectiveness of pharmacogenetic testing has been either general [58] or described eco-
nomic savings solely due to hypolipidemic effect of statins [59]. The first specific data for statin 
intolerance and its genetic testing appeared only very recently [60]–the authors estimated 356 
Canadian dollars as the cost limit for economic feasibility and at the same time dominant health 
effect for cardiovascular prevention. In extension of this very first report [60], this topic should 
be, therefore, addressed more intensively and also from other angles in the future. This has been 
the case with other pharmacogenetic applications (e.g. [61]), it will be also innovative to use new 
approaches which utilise alternative parameters for assessing effectiveness (e.g. [62–64]).
KEY MESSAGE
• Statins are the basis of dyslipidemia treatment in patients with increased cardiovascular risk.
• Genetic factors may predispose to statin intolerance.
• SCLO1B1 gene variation has strong association with statin-induced myopathy.
• Guidance for prescribers reflects individual risk for SLCO1B1 rs4149056 C allele carriers.
• Investigations of clinical relevance of other plausible gene variants are ongoing.
Pharmacogenetics of Cardiovascular Disease: Genetic Variation and Statin Intolerance
http://dx.doi.org/10.5772/intechopen.79518
133
Though important, inclusion of economic criteria is the only one part of the future priorities 
in the field of application of genetic variation for testing statin intolerance. Other avenues 
for future may address (1) further search for and verification of other genetic markers than 
SLCO1B1 including providing pharmacokinetic data [65, 66], (2) reflection of ethnic differ-
ences in distribution of genetic markers between populations [64, 67], (3) inclusion of the 
results of genetic test into electronic medical records [68], (4) performing meta-analyses of 
studies reported so far, and last but not least, (5) performance of well-designed clinical stud-
ies implementing also other non-genetic criteria in order to propose a risk-score or clinically 
applicable algorithm. The existing examples from other pharmacogenetic applications (e.g. 
[69]) and above described initiatives such as U-PGX [55], RNPGX [56], or the recent idea to 
provide patients with their DNA (pharmacogenetic) passport [70], allow us to expect further 
developments targeted at patient benefit and innovation of medical care.
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